Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. MicroPort Scientific Corporation
  6. News
  7. Summary
    853   KYG608371046

MICROPORT SCIENTIFIC CORPORATION

(853)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MicroPort Scientific : Clinical Trial Enrollment Completed for the First Endovastec™ Venous Stent

10/17/2021 EST

Beijing, China, 16 October 2021 - Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd. (Endovastec™) recently completed the final procedure of the pre-market multicenter clinical trial for the Vflower® Venous Stent System in Beijing, marking the completion of patient enrollment in the trial. The clinical trial for the Vflower® Venous Stent System is a prospective, multi-center, single-arm, nationwide clinical study led by Peking Union Medical College Hospital, in conjunction with The Affiliated Hospital of Qingdao University, and 12 medical centers as co-participators in China. It took just 10 months from the first implantation to the enrollment completion.

The Vflower® Venous Stent System is the first venous product developed by Shanghai Bluevastec MedTech Co., Ltd. (BluevastecTM), a subsidiary of EndovastecTM. Bluevastec™ leveraged the long-established technological foundation of Endovastec™ in vascular stents and delivery devices, coupled with in-depth research on venous morphological characteristics and hemodynamics for the design of this product. Vflower® features a braided structure that provides sufficient support to iliac vein compression and meets the flexibility requirement of distal vein. In addition, the unique design of its delivery system ensures a stable and precise release.

Existing follow-up results show that the Vflower® Venous Stent System has a 100% success rate in terms of device, technical and procedural success. This indicates that the System is able to precisely locate and effectively support the lesion site during a procedure to ensure unobstructed blood flow, as well as the stent's conformity to the physiology of the iliac vein. The completion of this clinical implantation of the Vflower® Venous Stent System fills a gap in the market of domestic venous stents, providing much needed assistance to patients.

Dr. Zhenyu Yuan, Vice President of Endovastec™ and General Manager of Bluevastec™, stated, "Bluevastec™ will continue to focus on developing more venous products and strengthen its product portfolio in this space through in-depth basic research and rich clinical research data to offer more cost-effective solutions for more patients with venous diseases. "

About Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd.

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™), which is a subsidiary of MicroPort Scientific Corporation, was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise, and the first batch of Specialized and New "Little Giant" Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.

Disclaimer

MicroPort Scientific Corporation published this content on 17 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 October 2021 02:30:01 UTC.


© Publicnow 2021
All news about MICROPORT SCIENTIFIC CORPORATION
11/28MICROPORT SCIENTIFIC : ® MedBot® Announces the Completion of the First Confirmatory Clinic..
PU
11/26MicroPort MedBot's Underwriters Fully Exercise Hong Kong IPO's Overallotment Option at ..
MT
11/26MICROPORT SCIENTIFIC : ® NeuroTech Obtains KGMP Certification
PU
11/26MICROPORT SCIENTIFIC : ® CRM Receives Approval in Japan for Alizea™ Bluetooth® Pacem..
PU
11/24MICROPORT SCIENTIFIC : Mona Lisa Robotic Prostate Puncture System Completes Enrollment of ..
PU
11/21MICROPORT SCIENTIFIC : ® Coronary Balloon Dilation Catheters Firefighter™ and Firefi..
PU
11/18MICROPORT SCIENTIFIC : ® RehabTech TherMotion® Cryo-Thermo Compression Device Approved for..
PU
11/17MICROPORT SCIENTIFIC : ® Announces Multiple Results from the TARGET Clinical Study on Fire..
PU
11/17MICROPORT SCIENTIFIC : ® MedBot Launches DFVision® 3D Electronic Laparoscope at the 28th N..
PU
11/15MICROPORT SCIENTIFIC : Ryflumen®, First Peripheral High-Pressure Balloon Dilatation Cathet..
PU
More news
Financials (USD)
Sales 2021 779 M - -
Net income 2021 -179 M - -
Net cash 2021 912 M - -
P/E ratio 2021 -40,8x
Yield 2021 0,07%
Capitalization 7 202 M 7 202 M -
EV / Sales 2021 8,07x
EV / Sales 2022 6,83x
Nbr of Employees 8 303
Free-Float 47,2%
Chart MICROPORT SCIENTIFIC CORPORATION
Duration : Period :
MicroPort Scientific Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MICROPORT SCIENTIFIC CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 4,01 $
Average target price 7,03 $
Spread / Average Target 75,2%
EPS Revisions
Managers and Directors
Zhao Hua Chang Chairman & Chief Executive Officer
Hong Bin Sun Chief Financial Officer
Qi Yi Luo Chief Technology Officer
Glendy Wang Chief Operating Officer
Jonathan H. Chou Independent Non-Executive Director
Sector and Competitors